• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 17th August 2010

Competition in the NHS: ‘Payment by Results’

Jon Sussex, Deputy Director of the OHE, researches incentives and competition in UK health services. In July, he presented findings on ‘Payment by Results’ to the Health and Social Care Conference held by the Association of Chief Executives of Voluntary…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

Jon Sussex, Deputy Director of the OHE, researches incentives and competition in UK health services. In July, he presented findings on ‘Payment by Results’ to the Health and Social Care Conference held by the Association of Chief Executives of Voluntary Organisations.

Jon Sussex, Deputy Director of the OHE, researches incentives and competition in UK health services.  In July, he presented findings on ‘Payment by Results’ to the Health and Social Care Conference held by the Association of Chief Executives of Voluntary Organisations.

‘Payment by Results’ (PbR) was instituted in the NHS in England in 2003 to stimulate provider efficiency, encourage health care purchasers to plan and manage demand better, enable patient choice, reward quality in service provision and be transparent.  Money was to follow the patient.  Previously hospitals were funded mainly by block contracts, which provided little incentive for increasing patient access to care.

PbR uses units of activity similar to DRGs in other countries. It provides a fixed price for a unit of activity: an inpatient or day-case ‘spell’, first or follow-on outpatient treatment, or A&E attendance.   PbR applies to most NHS-funded acute hospital care in England and applies to care from all providers – third-sector and private hospitals as well as public hospitals.

Critics of PbR have questioned its effects, charging that it may have increased unnecessary care, discouraged moving care to other settings, scrimped on quality to reduce unit cost, led to recoding care at higher price levels (‘upcoding’), and discouraged treating the sickest/most expensive patients.  These assumptions were tested by quantitative and qualitative research performed by Aberdeen University and the OHE that compared  activity in hospitals subject to PbR to those not subject to it.

The research showed a slight increase in efficiency, measured by length of stay (days) and proportion of day cases.  Spells, i.e. the volume of activity, did increase slightly although the data do not show whether any was for ‘unnecessary’ care.  Quality was not affected adversely when measured by rates of in-hospital mortality, 30-day post surgical mortality and emergency re-admissions after treatment for hip fractures.  With respect to upcoding, the evidence is mixed, with shifts observable in maternity care but not elsewhere.

PbR may be less successful, however, in achieving its objective of stimulating competition on attributes of care other than price.  This may be in part because charity and private providers are at a financial disadvantage in two respects.  First, NHS pensions are subsidized by taxpayers, while those of other institutions are not, amounting to a difference of 6-7% in total costs.  Second, VAT differences, e.g., on services that are contracted out, amount to approximately 3.5% on the price. 

In future, PbR is likely to be expanded to include mental health and community services.  National ‘best practice’ tariffs are likely in several additional treatment areas, encouraging more day-case care, streamlining patient care pathways and encouraging best-practice care.  These will be supplemented by local quality incentives including: (1) the Commissioning for Quality and Innovation (CQUIN) payment framework, which makes a proportion of providers’ income conditional on quality and innovation and (2) payment-for-performance (P4P) schemes.

Still uncertain is how the new tariffs may be constructed with respect to units of activity, disaggregation of treatment, and unbundling.  With changes under the new Government, it’s also not clear who will be making decisions about which care to purchase from where – GP consortia, individual physicians, patients or another provider.  No matter how the situation develops, however, providers of mental health and community services should prepare by collecting good data on what services are provided for what kinds of clients/patients and at what cost – including both structures (fixed v. marginal; ‘common’ v. specific) and levels.

  • Healthcare Systems
  • Competition

Related News

  • News
  • May 2019

OHE Lunchtime Seminar: Incentives for R&D, Competition and Intertemporal Effects of Payment Rules for Cures

Read more
  • News
  • November 2018

OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages

Read more
  • News
  • November 2018

OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages

Read more
  • News
  • September 2018

Private Provision of Publicly Funded Health Care: The Economics of Ownership

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!